Sale

Influenza Vaccine Market

Global Influenza Vaccine Market Share, Size, Growth, Trends, Forecast: By Vaccine Type: Quadrivalent, Trivalent; By Technology: Egg Based, Cell Based; By Age Group: Pediatric, Adult; By Route of Administration: Injection, Nasal Spray; By Distribution Channel: Hospital Pharmacy, Others; Regional Analysis; Supplier Landscape; 2024-2032

Global Influenza Vaccine Market Outlook

The global influenza vaccine market value was USD 6.33 billion in 2023, driven by increased awareness about the health risks associated with influenza across the globe. The market size is anticipated to grow at a CAGR of 7.3% during the forecast period of 2024-2032 to achieve a value of USD 11.94 billion by 2032.

 

Global Influenza Vaccine Market: Introduction and Insights

An influenza vaccine, variously known as a flu vaccine, is a vaccine that provides protection against the various strains of influenza. As influenza is most prevalent in the monsoon season, the vaccine prevents the risk of influenza-related complications like ear infections and bacterial pneumonia. An influenza vaccine is one of the most crucial vaccinations to bolster the quality of life.

 

Global Influenza Vaccine Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The increasing awareness regarding the benefits of influenza to prevent adverse side effects of influenza infection is augmenting the market growth. Various governments bodies such as the Food and Drug Administration (FDA) of the United States and the European Commission, among others, are increasingly authorising effective influenza vaccines. This, in turn, is preventing the spread of the disease and increasing the healthcare quality, hence driving the market growth. Furthermore, the growing demand for innovative zoonotic influenza vaccines to prevent the potential spread of influenza from animals is providing impetus to the growth of the market.

 

The market for influenza vaccine is being aided by the growing demand for influenza vaccines in developing countries due to the high prevalence of influenza-related deaths. Moreover, various governments are increasingly providing influenza vaccines for children to prevent the surge of complicated health issues. As the monsoon season in developing countries results in a surge in cases of influenza, routine administration of vaccines against the disease is recommended, which is significantly contributing to the growth of the market. In addition, the initiation of various research activities by governments to develop a vaccine that provides protection against various strains of the influenza virus is predicted to drive the market growth in the forecast period.

 

Influenza Vaccine Market Segmentations

The market can be segmented on the basis of vaccine type, technology, route of administration, age group, distribution channel, and major region.

 

Global Influenza Vaccine Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Breakup by Vaccine Type

  • Quadrivalent
  • Trivalent

 

Market Breakup by Technology

  • Egg-based
  • Cell-based

 

Market Breakup by Route of Administration

  • Injection
  • Nasal Spray

 

Market by Age Group

  • Paediatric
  • Adult

 

Market Breakup by Distribution Channel

  • Hospitals
  • Retail Pharmacies
  • Government Suppliers
  • Others

 

Market Breakup by Region

  • North America
    • United States of America
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others

 

Key Trends in the Influenza Vaccine Market

The market growth is being aided by the growing adoption of cold-adapted influenza virus vaccines to boost the efficacy and safety of vaccination. Such vaccines do not result in any adverse side effects, due to which they are increasingly preferred for children. As cold-adapted vaccines can be administered through a nasal spray, they are ideal for the trypanophobia population, which is bolstering the growth of the market. Moreover, the increasing approvals of cold-adapted influenza vaccines by healthcare bodies are driving the growth of the influenza vaccine market.

 

Global Influenza Vaccine Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Advancements in vaccination technology are leading to the development of influenza vaccines from negative-strand RNA virus, which is predicted to propel the growth of the market. Moreover, the development of effective mRNA vaccines against SARS-CoV-2 during the COVID-19 crisis is leading to a surge in research activities to develop efficient mRNA influenza vaccines, which is expected to significantly contribute to the market growth.

 

In addition, various studies and clinical trials are initiated by leading companies to determine the benefits, immunogenicity, and safety of the mRNA influenza vaccine.

 

Global Influenza Vaccine Market- Competitive Landscape

The report presents a detailed analysis of the following key players in the global influenza vaccine market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

 

  • AstraZeneca plc
  • Biodiem Limited
  • CSL Limited
  • Emergent BioSolutions Inc.
  • F. Hoffmann-La Roche AG
  • Gamma Vaccines Pty Ltd
  • GlaxoSmithKline Plc.
  • Merck and Co., Inc.
  • Pfizer Inc.
  • Sanofi S.A.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Vaccine Type
  • Technology
  • Age Group
  • Route of Administration
  • Distribution Channel
  • Region
Breakup by Vaccine Type
  • Quadrivalent
  • Trivalent
Breakup by Technology
  • Egg Based
  • Cell Based
Breakup by Age Group
  • Pediatric
  • Adult
Breakup by Route of Administration
  • Injection
  • Nasal Spray
Breakup by Distribution Channel
  • Hospital Pharmacy
  • Government and Institution Supply
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • AstraZeneca plc
  • Biodiem Limited
  • CSL Limited
  • Emergent BioSolutions Inc.
  • F. Hoffmann-La Roche AG
  • Gamma Vaccines Pty Ltd
  • GlaxoSmithKline Plc.
  • Merck and Co., Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Others

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope
    1.4    Research Methodology
2    Executive Summary
3    Influenza Overview

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Influenza Epidemiology Analysis
    5.1    Epidemiology Overview (2016-2031)
    5.2    North America Influenza Epidemiology (2016-2031)
    5.3    Europe Influenza Epidemiology (2016-2031)
    5.4    Asia-Pacific Influenza Epidemiology (2016-2031)
    5.5    Latin America Influenza Epidemiology (2016-2031)
    5.6    Middle East & Africa Influenza Epidemiology (2016-2031)
6    Global Influenza Vaccine Market Overview 
    6.1    Global Influenza Vaccine Market Historical Value (2017-2023) 
    6.2    Global Influenza Vaccine Market Forecast Value (2024-2032)
7    Global Influenza Vaccine Market Landscape
    7.1    Global Influenza Vaccine Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Global Influenza Vaccine Product Landscape
        7.2.1    Analysis by Vaccine Type
        7.2.2    Analysis by Technology
        7.2.3    Analysis by Age Group
8    Influenza Vaccine Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Global Influenza Vaccine Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model 
    10.4    Key Demand Indicators
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends 
    10.7    Value Chain Analysis
11    Global Influenza Vaccine Market Segmentation
    11.1    Global Influenza Vaccine Market by Vaccine Type
        11.1.1    Market Overview
        11.1.2    Quadrivalent
        11.1.3    Trivalent
    11.2    Global Influenza Vaccine Market by Technology
        11.2.1    Market Overview
        11.2.2    Egg Based 
        11.2.3    Cell Based
    11.3    Global Influenza Vaccine Market by Age Group
        11.3.1    Market Overview
        11.3.2    Pediatric
        11.3.3    Adult
    11.4    Global Influenza Vaccine Market by Route of Administration
        11.4.1    Market Overview
        11.4.2    Injection
        11.4.3    Nasal Spray
    11.5    Global Influenza Vaccine Market by Distribution Channel
        11.5.1    Market Overview
        11.5.2    Hospital Pharmacy
        11.5.3    Government and Institution Supply
        11.5.4    Others
    11.6    Global Influenza Vaccine Market by Region
        11.6.1    Market Overview
        11.6.2    North America 
        11.6.3    Europe
        11.6.4    Asia Pacific
        11.6.5    Latin America
        11.6.6    Middle East and Africa
12    North America Influenza Vaccine Market
    12.1    Market Share by Country
    12.2    United States of America
    12.3    Canada
13    Europe Influenza Vaccine Market
    13.1    Market Share by Country
    13.2    United Kingdom
    13.3    Germany
    13.4    France
    13.5    Italy
    13.6    Others
14    Asia Pacific Influenza Vaccine Market
    14.1    Market Share by Country
    14.2    China
    14.3    Japan
    14.4    India
    14.5    ASEAN
    14.6    Australia
    14.7    Others
15    Latin America Influenza Vaccine Market
    15.1    Market Share by Country
    15.2    Brazil
    15.3    Argentina
    15.4    Mexico
    15.5    Others
16    Middle East and Africa Influenza Vaccine Market
    16.1    Market Share by Country
    16.2    Saudi Arabia
    16.3    United Arab Emirates
    16.4    Nigeria
    16.5    South Africa
    16.6    Others
17    Patent Analysis
    17.1    Analysis by Type of Patent
    17.2    Analysis by Publication year
    17.3    Analysis by Issuing Authority
    17.4    Analysis by Patent Age
    17.5    Analysis by CPC Analysis
    17.6    Analysis by Patent Valuation 
    17.7    Analysis by Key Players
18    Grants Analysis
    18.1    Analysis by year
    18.2    Analysis by Amount Awarded
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Grant Application
    18.5    Analysis by Funding Institute
    18.6    Analysis by NIH Departments
    18.7    Analysis by Recipient Organization
19    Clinical Trials Analysis 
    19.1     Analysis by Trial Registration Year 
    19.2    Analysis by Trial Status 
    19.3    Analysis by Trial Phase 
    19.4    Analysis by Therapeutic Area 
    19.5    Analysis by Geography  
20    Funding Analysis
    20.1    Analysis by Funding Instances
    20.2    Analysis by Type of Funding
    20.3    Analysis by Funding Amount
    20.4    Analysis by Leading Players
    20.5    Analysis by Leading Investors
    20.6    Analysis by Geography
21    Partnership and Collaborations Analysis
    21.1    Analysis by Partnership Instances
    21.2    Analysis by Type of Partnership
    21.3    Analysis by Leading Players
    21.4    Analysis by Geography
22    Regulatory Framework
    22.1    Regulatory Overview
        22.1.1    US FDA
        22.1.2    EU EMA
        22.1.3    INDIA CDSCO
        22.1.4    JAPAN PMDA
        22.1.5    Others
23    Supplier Landscape
    23.1    AstraZeneca plc
        23.1.1    Financial Analysis
        23.1.2    Product Portfolio
        23.1.3    Demographic Reach and Achievements
        23.1.4    Mergers and Acquisitions
        23.1.5    Certifications
    23.2    Biodiem Limited
        23.2.1    Financial Analysis
        23.2.2    Product Portfolio
        23.2.3    Demographic Reach and Achievements
        23.2.4    Mergers and Acquisitions
        23.2.5    Certifications
    23.3    CSL Limited
        23.3.1    Financial Analysis
        23.3.2    Product Portfolio
        23.3.3    Demographic Reach and Achievements
        23.3.4    Mergers and Acquisitions
        23.3.5    Certifications
    23.4    Emergent BioSolutions Inc.
        23.4.1    Financial Analysis
        23.4.2    Product Portfolio
        23.4.3    Demographic Reach and Achievements
        23.4.4    Mergers and Acquisitions
        23.4.5    Certifications
    23.5     F. Hoffmann-La Roche AG
        23.5.1    Financial Analysis
        23.5.2    Product Portfolio
        23.5.3    Demographic Reach and Achievements
        23.5.4    Mergers and Acquisitions
        23.5.5    Certifications
    23.6    Gamma Vaccines Pty Ltd
        23.6.1    Financial Analysis
        23.6.2    Product Portfolio
        23.6.3    Demographic Reach and Achievements
        23.6.4    Mergers and Acquisitions
        23.6.5    Certifications
    23.7    GlaxoSmithKline Plc.
        23.7.1    Financial Analysis
        23.7.2    Product Portfolio
        23.7.3    Demographic Reach and Achievements
        23.7.4    Mergers and Acquisitions
        23.7.5    Certifications
    23.8    Merck and Co., Inc.
        23.8.1    Financial Analysis
        23.8.2    Product Portfolio
        23.8.3    Demographic Reach and Achievements
        23.8.4    Mergers and Acquisitions
        23.8.5    Certifications
    23.9    Pfizer Inc.
        23.9.1    Financial Analysis
        23.9.2    Product Portfolio
        23.9.3    Demographic Reach and Achievements
        23.9.4    Mergers and Acquisitions
        23.9.5    Certifications
    23.10    Sanofi S.A.
        23.10.1    Financial Analysis
        23.10.2    Product Portfolio
        23.10.3    Demographic Reach and Achievements
        23.10.4    Mergers and Acquisitions
        23.10.5    Certifications
    23.11    Others
24    Global Influenza Vaccine Market- Distribution Model (Additional Insight)
    24.1    Overview 
    24.2    Potential Distributors 
    24.3    Key Parameters for Distribution Partner Assessment
25    Key Opinion Leaders (KOL) Insights (Additional Insight)
26    Company Competitiveness Analysis (Additional Insight)

    26.1    Very Small Companies
    26.2    Small Companies
    26.3    Mid-Sized Companies
    26.4    Large Companies
    26.5    Very Large Companies 
27    Payment Methods (Additional Insight)
    27.1    Government Funded
    27.2    Private Insurance
    27.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The influenza vaccine market was valued at USD 6.33 billion in 2023.

The market is expected to grow at a CAGR of 7.3% from 2024 to 2032 to reach a value of USD 11.94 billion by 2032.

The market is being aided by the rising awareness regarding the importance of influenza vaccines, the growing authorisation of vaccines, and the high prevalence of influenza-related issues in developing countries.

The market is expected to be propelled by the growing adoption of cold-adapted influenza vaccines, advancements in vaccines technology, and the initiation of clinical trials for the development of new and innovative influenza vaccines.

The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The different types of vaccine include quadrivalent and trivalent.

The technologies in the market include egg-based and cell-based, among others.

The routes of administration include injection and nasal spray.

The age groups can be categorized into paediatric and adult.

The distribution channels can be categorised into hospitals, retail pharmacies, and government suppliers, among others.

The key players in the market include AstraZeneca plc, Biodiem Limited, CSL Limited, Emergent BioSolutions Inc., Gamma Vaccines Pty Ltd, GlaxoSmithKline Plc., Merck and Co., Inc., Pfizer Inc., Sanofi S.A., and F. Hoffmann-La Roche AG.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER